Stay updated with breaking news from Glycomimetics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com began coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a research report sent to investors on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock. Other analysts have also recently issued research reports about the company. Capital One Financial cut GlycoMimetics from an overweight rating to an equal weight […]
.png?height=418&t=1670008838&width=800)
Top-line data from Glycomimetics Inc.’s pivotal phase III study of uproleselan in 388 patients with relapsed/refractory acute myeloid leukemia missed its primary endpoint. The data crippled the stock, which closed at the low point of its 10-year existence.
GlycoMimetics, Inc. (GLYC) reported topline results from Phase 3 global pivotal study of uproleselan in 388 patients with Relapsed/Refractory Acute Myeloid Leukemia.
Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect...
